

# The appropriate evaluation of HIV prevention interventions: from experiment to full scale implementation.

Timothy B Hallett\*, Peter J White & Geoff P Garnett  
Department of Infectious Disease Epidemiology, Imperial College London

\* To whom correspondence should be addressed: timothy.hallett@imperial.ac.uk

---

Online First Manuscript,  
December 2006

---

## Abstract

**Background.** Preventing HIV infection is still an essential goal in tackling the HIV/AIDS pandemic. Remarkably little is known about how best to reduce HIV incidence because the majority of trials focus on the reduction of risk behaviours and assume an effect on HIV incidence.

**Objectives.** To discuss the evidence for the effectiveness of HIV prevention strategies, exploring the different types of evidence available, including individual and community randomised controlled trials and observational studies.

**Results.** Whilst providing a gold standard for evidence, trials have been limited in their scope and are difficult to interpret and generalise. There have been examples of national level successes in preventing HIV which have been detected in surveillance data and understood through behavioural and modelling studies. These have the advantage of being to scale and indicating effectiveness rather than efficacy.

**Conclusions.** Whilst randomised trials are important because of their scientific rigor, it is also important that evidence from observational epidemiology is not overlooked. Only if good quality, consistent data are available can the history of the HIV epidemic be appropriately analysed.

## Key Messages

1. Demonstrating that an intervention is successful at changing individual sexual behaviour does not necessarily mean it is effective at reducing the transmission of sexually transmitted infections.
2. Community-randomised control trials are the best standard of evidence of the effectiveness of an intervention but questions remain about impact at a larger scale, and how strongly study design influences whether there is a significant beneficial outcome.
3. High quality sentinel surveillance data in conjunction with behavioural and modelling studies can be used to assess the effectiveness of scaled-up interventions.

## Key Words

HIV; Intervention; Evaluation; Mathematical Modelling; Randomised Control Trials

## Introduction

Globally, substantial resources have been committed to the treatment and prevention of HIV and AIDS<sup>1</sup> and advances are being made in providing antiretroviral treatments in resource poor settings<sup>2</sup>. Such advances will be unsustainable without successes in HIV prevention<sup>3</sup>. However, remarkably little is known about the effectiveness of preventive interventions in reducing HIV incidence itself<sup>4</sup>. In part, the 'emergency' nature of the HIV epidemic has required implementation of interventions to run ahead of evidence of effectiveness. In planning a response to the global pandemic assumptions have been made about what works using limited evidence from theory, the measurement of processes or intermediate intervention outcomes, such as behaviour change<sup>5</sup>.

Here we discuss how interventions have been evaluated and interpreted and the epidemiological and methodological issues that have been learned. National surveillance, with behavioural data collection as an adjunct, can provide the most powerful and relevant test of HIV interventions.

### Individual Randomised controlled trials

The randomised controlled trial (RCT) provides the 'gold standard' for testing the efficacy of medical interventions, providing a clear experimental design to demonstrate the presence or absence of an effect<sup>6,7</sup>. This study design works well when there is a straightforward replicable intervention linked to the disease outcome.

The majority of RCTs in research on HIV prevention use outcome measures of risk behaviour rather than HIV incidence itself. This is appropriate for interventions aimed at HIV-positive individuals, which show decreased unprotected sex and STIs (sexually transmitted infections)<sup>8</sup>, and when the STIs are themselves the outcome of interest<sup>9</sup>. It is less clear how useful intermediate outcomes are in other situations in either exploring the risks of HIV in the individual or in the community. For example, a recent measure of an HIV intervention in a community in Uganda found that both condom use increased and numbers of sex partners decreased<sup>10</sup>. Whilst a trial of circumcision in South Africa showed a 60% reduction in HIV incidence in circumcised men, other risk behaviours (e.g. number of sexual partnerships and frequency of unprotected sex) in those men increased<sup>11</sup>. Many HIV intervention trials have now been performed and are summarised in systematic reviews, but the focus has been on how to change risk behaviour, with an concentration in the United States and on Men Who Have Sex With Men<sup>12-15</sup> and less emphasis on developing country populations<sup>16</sup> or on HIV incidence as an outcome.

For a number of reasons interventions to prevent the spread of HIV are not always readily assessed in individual randomised controlled trials.

1. A key problem is the low incidence of HIV in many industrialised countries where intervention trials are well resourced. The adoption of intermediate outcomes such as increased condom use, reduced numbers of sexual partners or reduced incidence of other sexually transmitted infections is common. Data on self-reported behaviour change may be unreliable. Even if the changes are genuine it is not clear that such changes will actually alter HIV incidence depending as they do on the epidemiological context<sup>4</sup>. Changes in risk behaviour could be overwhelmed by high levels of exposure or could differentially influence lower risk contacts. Even where HIV incidence is sufficiently high to measure without prohibitively-large sample sizes, the complexity and cost of measuring incident HIV infection has led to the use of proxy outcomes.
2. HIV-prevention interventions are often complex, requiring skilled staff to carry out counselling and education to motivate and facilitate the adoption of safer sexual behaviours. Difficulties in ensuring that interventions are appropriately implemented create uncertainty about negative trial results and concerns about replicating the intervention outside the context of the trial.
3. Other HIV interventions are not amenable to individual randomisation if the focus is the group, community or population. For example the use of mass-media advertising or educational drama can only be delivered to groups.
4. Conceptually, the focus on individuals may not be appropriate since individual behaviour is greatly affected by social and cultural norms, making interventions targeted only at selected individuals largely ineffective. This is particularly the case with sexual behaviour which must involve at least one other person. These norms vary between settings and through time within a setting, limiting the generalisability of RCT findings.

The relationship between behaviour and risk of infection is complex and dynamic. An individual's risk of acquiring an infection depends not only upon their behaviour but also their position within the dynamic network of contacts through which infection spreads<sup>17</sup>. This is particularly important in the case of STIs and HIV, where there is extreme heterogeneity in individual sexual behaviours and hence in the risk of acquiring and transmitting infection, with a small group of individuals dominating the spread of infection<sup>18,19</sup>. At a population level, the impact of an individual changing their number or choice of sexual partners or their treatment-seeking behaviour for STI symptoms, or the course of infectiousness over time, all depend upon their role in the transmission dynamics of the infection<sup>4,18</sup>.

### Community Randomised Controlled Trials

The failure of individual-level trials to determine the community-level impact of interventions has led to a number of community randomised controlled trials (CRCTs) of HIV and STI interventions<sup>20-23</sup>. In these, the intervention is targeted at communities, which are randomised to treatment or control arms. Randomisation is used to distribute all the differences between the communities (known and unknown) evenly to both arms of the trial. The appropriate circumstances for a CRCT have been listed by Susser<sup>24</sup> as requiring 1) A well-defined, narrow hypothesis; so that the

key to the intervention success or failure can be identified; 2) A measurable intervention; in order to be able to assess its implementation; 3) Adequate statistical power; and 4) Well-defined, measurable outcomes. Unfortunately, the first three criteria are often absent in CRCTs aimed at preventing HIV. The complexity of HIV interventions and their delivery can be a problem for CRCTs just as it can for individual RCTs, but CRCTs also suffer from their scale, which presents major challenges of logistics and resources often leading to compromises in the number of communities randomised. Since health promotion builds over time as knowledge increases and cultural norms and practices change, it is likely that it will take some time for the interventions to impact on incident HIV. Furthermore, the effect of changes in one group can take time to percolate to the rest of the population (Hallett *et al.*, submitted). The extended follow-up period thus required increases the risks of study biases caused by poor follow-up rates, migration and changes in the background epidemiological context, such as epidemic maturation or an increase in the availability of anti-retroviral therapy.

The impact of STI control on HIV transmission has been a focus of CRCTs in the HIV field with conflicting results. In HIV epidemiology the question of whether the presence of another sexually transmitted infection increased susceptibility to, or transmissibility of, HIV could not be addressed using observational epidemiological studies. Other STIs and HIV have common risk-factors which cannot be adequately controlled for by measuring their influence in individuals. The Mwanza Trial of syndromic management of STIs was a ground breaking study in 12 communities in Tanzania, which found 40% lower HIV incidence in all 6 intervention communities when compared to their matched control communities<sup>20</sup>. However, subsequent trials which have included: mass antibiotic administration, aimed at controlling asymptomatic STIs, in the Rakai, Uganda<sup>21</sup>; the use of syndromic management of STIs in one arm combined with Information, Education and Communication in a third arm in Masaka, Uganda<sup>22</sup>; and the use of syndromic management combined with peer-led education targeting high-risk sexual behaviours in Manicaland, Zimbabwe<sup>23</sup> have all shown no population-level impact on the incidence of HIV infections, despite changing patterns of risk within the intervention communities. The last provides an interesting example, where the result could be over-interpreted in determining policy on how much STI control through syndromic management should be a part of HIV prevention, since bacterial STIs were already well controlled and the main focus of the study was the behavioural intervention.

#### ***Interpreting positive CRCT results***

A positive result of a community randomised trial is unequivocal in demonstrating that the intervention has worked. However, questions remain: What are the necessary components of the intervention? What quality of intervention is required to maintain effectiveness in other settings? How well can the intervention be scaled up to a wider population or to a national level? – Essentially there is a problem translating the *efficacy* observed in trial conditions to an *effectiveness* at a larger scale since interventions are often implemented less well when scaled up (i.e. they can be less intensive, less carefully monitored, and carried out in unselected populations with lower motivation). The costs of the intervention will likely be less outside the trial setting but at the same time this could compromise the effectiveness. In addition to problems of scale there is the question of whether the intervention will work in other epidemiological, social and cultural contexts. For example, the syndromic management of STIs significantly reduced HIV incidence in the Mwanza trial<sup>21</sup> but this result has not been reproduced in the other trials of STI control targeting HIV incidence. The influence of the other sexually transmitted infections appears to be greatest in the early stages of an HIV epidemic where infection is concentrated in high risk parts of the population and when the curable bacterial STIs are more important than infections such as genital herpes, which cannot be cured<sup>25</sup>.

#### ***Interpreting negative CRCT results***

Negative CRCT results are even more difficult to interpret. They tell us that the intervention, as implemented, did not produce significant results, but there are a number of potential explanations. The study may have been inadequately powered because sample-size calculations require knowledge of the variation of incidence between the populations studied, and accurate forecasts of future patterns of incidence without interventions (Hallett *et al.*, submitted). Because of the dynamic nature of epidemics such future patterns may not be consistent with past incidence rates, and variation in recorded prevalence at baseline may be a misleading proxy of variation in incidence. Implementation of the interventions may not have been adequate; however, since *effectiveness* is more important than *efficacy*, and since within intervention trials the interventions are likely to be more assiduously implemented than when scaled-up, this may seem a minor problem. Nonetheless, the complex nature of many interventions means that a failure of implementation rather than efficacy can be claimed and failing interventions be continued. More reasonably, the generalisability of the negative result to other epidemiological contexts can be debated. For individual RCTs, repetition of the trial in the same and in other contexts can eliminate doubts through comparison and meta-analyses of multiple trials. Unfortunately, that is not easily achieved with long and costly CRCTs.

#### **Observational studies**

The urgency required in responding to the spread of a lethal infectious disease has led to many interventions being implemented before the evidence from trials has become available. In some cases where large-scale interventions have been implemented, associated observational epidemiological and behavioural studies have identified changes in HIV

prevalence which can only be attributed to changes in HIV incidence and have been linked to changes in specific risk behaviours<sup>26-30</sup>. Such observational studies have the advantage of assessing interventions at the regional or national scale. This immediately avoids many problems of trials, as the interventions are already to scale and measure effectiveness. However, in the hierarchy of evidence, such observational epidemiology is considered to be weak. Biases such as changes in the representativeness of antenatal clinics included in sentinel surveillance, changes in fertility due to HIV affecting ANC data<sup>31</sup>, trends unrelated to the interventions, and the natural dynamics of STI and HIV incidence can lead to spurious measures of success or failure. Nonetheless, if such biases can be predicted and measured their effects can be excluded<sup>32</sup> and powerful arguments of what works can be based on observational epidemiological data.

In the late 1980s and early 1990s, in response to the high prevalence of HIV, the government of Uganda implemented an HIV prevention strategy acknowledging and promoting the discussion of HIV risks and advocating a reduction in sexual risk behaviour<sup>33</sup>. The prevalence of infection was seen to decline in young women attending antenatal clinics. Cross-sectional population-based survey data showed decreases in reported numbers of sexual partners<sup>26,33</sup>. Such declines, particularly in those too young to have been removed by HIV-associated death and sub-fertility, could only be explained if HIV incidence had declined and provided a much-needed national level success story. Subsequent debate has continued over the cause of the success, with the neologism ABC – *abstinence, be faithful, use condoms* – being introduced, and competing claims being made over the relative importance of condom use and abstinence<sup>33,34</sup>. A similar national level change in patterns of prevalence and incidence was achieved in Thailand. Here, studies that found sex work was the major focus of HIV transmission led to an intervention that both discouraged clients from purchasing sex and encouraged universal condom use by sex workers. Behaviour change was observed - very high rates of condom use amongst sex workers and decreased reported visits to sex workers – and was complemented by biological outcomes: reduced incidence of STDs and HIV in military recruits. At the population level this translated into reduced prevalence of HIV amongst women attending antenatal clinics in sentinel surveillance<sup>28,29</sup>.

These two examples have had a profound impact on discussion of HIV prevention strategies, but had not been repeated until recently. In recent years HIV prevalence has declined from very high levels in a few countries, including Zimbabwe and parts of urban Kenya<sup>35</sup>. As in the case of Uganda, the current observations are of declines in HIV prevalence, a measure reflecting cumulative risk, rather than HIV incidence, which would provide a more up-to-date information. Care needs to be taken in analysing declines in prevalence because the natural pattern of incidence (i.e. without any behaviour change) in an epidemic is to increase until the at-risk population is saturated and then to decline to a new lower level matching the supply of new susceptible individuals (Figure 1)<sup>36</sup> STI supplement, Criteria for... Prevalence can then fall if HIV-mortality associated with the earlier higher incidence exceeds the acquisition of new infections. Such a decline could be expected approximately a decade after the period of most rapid HIV spread. These natural dynamics need to be excluded as an explanation of decreases in HIV prevalence if we are to detect success in HIV control. The trends in prevalence observed in Zimbabwe and parts of urban Kenya could not be reproduced by a 'null model' of these natural dynamics<sup>37</sup>. Observational studies exploring national reductions in HIV prevalence require mathematical models of the transmission dynamics of HIV to create a null model describing the trajectories of incidence and prevalence in the absence of the intervention. It is then possible to compare the observed data with this null model to estimate the impact of the intervention<sup>25,27,33,37</sup>. Such analyses can give striking insights; for example, it was estimated that the decline in prevalence in Uganda was mediated by a reduction in incidence roughly equivalent to an 80% efficacious vaccine given to everyone in the population<sup>33</sup>.

The analyses of HIV trends in Zimbabwe and Kenya were restricted to those antenatal clinics sampled continuously over time. This will have limited the extent to which the country's population is represented as such clinics are mostly located in urban centres. However, it avoids the artificial declines in prevalence that could be expected from the recent expansion of clinics to include those serving more rural populations over recent years. The requirement for settings with consistently sampled clinics will limit the number of places where prevalence trends can be explored. Another way of dealing with problem of sampling biases which change over time is to explicitly explore them. The comparison of random population-based surveys with sentinel surveillance data allows the identification of biases, which can then be included in mathematical models. For example, there is a concern that HIV associated sub-fertility will increase over the course of an infection thereby decreasing the proportion of HIV infected women becoming pregnant as an epidemic ages. In mathematical models this effect is counteracted by decreases in sterility associated with past infections with bacterial STIs and occurs early in the spread of the virus<sup>32,37</sup>.

Once we are confident that declines in HIV prevalence exceed those expected from the natural dynamics the obvious question is what has caused the declines. Questions of attribution are important as we need to know which risks are amenable to change and how they might be changed. There are two causal levels of interest: first, what change in the distribution of risk explains the reduction in HIV incidence, and second, can these changes in risk be attributed to particular interventions? Unfortunately, in Uganda there has been much scope for speculation and appropriation of the success story to support *a priori* beliefs because of the lack of representative, contemporaneous and detailed risk-behavioural data. However, despite the lack of behavioural data it is possible to draw some conclusions from the observed pattern of prevalence decline. Fitting a model to the decline in Kampala shows that the reduction in aggregate risk must have begun during the late 1980s (Figure 2), which suggests it is unlikely to have been driven by the increased use of socially marketed condoms that happened later<sup>33,34</sup>. On the other hand, it seems that the dramatic turnaround would not have been possible without all three types of behaviour change across the population i.e. delaying commencing sexual activity by two years, lowering partner change rates and increasing condom use<sup>26,27,33</sup> (Figure 2).

In Zimbabwe the situation is clearer because the observed national-level decline in HIV prevalence<sup>38</sup> coincided with population based surveys of sexual behaviour in the rural eastern highlands<sup>30</sup> and observed reductions in incidence among post-natal women and male factory workers in the urban population<sup>39</sup>. The former suggested that in these rural communities declines in numbers of sexual partners and an increase in age of sexual debut were associated with the changing incidence, but the latter observed that an increase in condom use was associated with changes in risk in Harare. Behavioural data can be used to identify the components leading to HIV declines when the observed behaviour changes can have a direct influence on the risk of acquisition and transmission of HIV and other similar risk behaviours have not changed. Only if the proximate determinants of HIV infection change can interventions alter the course of the HIV epidemic. The proximate determinants of HIV incidence are those factors influencing (i) exposure of uninfected individuals to HIV-positive individuals, (ii) the transmission probability of the virus when such exposure occurs, and (iii) the duration of infectiousness of HIV-positive individuals<sup>40</sup>. Social, demographic, economic, and other, factors that affect HIV incidence ultimately act through their effect on these proximate determinants.

Beyond attributing reduced HIV incidence to particular behaviour changes, relating those behaviour changes to particular interventions requires data measuring exposure to the interventions, perceived responses to those interventions and plausible mechanisms linking the interventions and the observed changes. Such attribution will always be weak if there are multiple interventions and societal changes. A failure to change risk over the long term may be indicative of unsuccessful interventions, but behaviour change that is consistent with an intervention's goals suggests that the intervention has worked and that the replication and expansion of the approaches taken might be warranted. Too often such evidence is ignored because it does not meet the requirements of "rigorous" evaluation. Although observed trends in risks within populations do not provide definitive evidence of the failure or success of an intervention generally, the same is true for CRCTs where results from trial of interventions designed to target specific groups or behaviours cannot be generalised.

Using national-level surveillance data is not suitable for all epidemiological questions. It would not be possible to resolve the difference between the natural, intrinsic course of the epidemic from an epidemic where extrinsic changes alter the course of a growing epidemic (i.e. when incidence has not already reached a peak) because patterns of risk cannot be adequately assessed in order to predict the peak prevalence. If behaviour changes before the incidence saturates, then the epidemic will settle to a lower level than it would have otherwise but the decline in prevalence will look like the natural dynamics only, leading to the erroneous conclusion that behaviour has not changed (Figure 1).

A further problem is the ability of surveys of risk behaviour to capture the details of sexual behaviour necessary to accurately assess the potential for epidemic spread. The distribution of numbers of sexual partners, the pattern of sexual partner choice, the overlap between sexual partners, and the number and type of sex-acts within partnerships, all influence the acquisition and transmission of HIV and many advances in study design have improved our ability to measure such detail. However, some uncertainty is inevitable: details about the sexual contact of one's sexual contacts cannot be measured in ordinary population-based surveys and since the highest-risk individuals are typically a small proportion of the population— and may be under-represented in household surveys (e.g. sex workers, injecting drug users) – it is difficult to obtain reliable estimates of their behaviour although they contribute disproportionately to the transmission. This matters if declines in HIV incidence are not explained in surveys or if observed changes are insufficient to explain the magnitude of declines. However, it is unlikely that less-obvious changes in behaviour will explain dramatic decreases in HIV incidence, especially as surveys are well-designed, with reasonably-large sample sizes.

The expansion in funding for HIV prevention activities associated with the creation of the Global Fund for AIDS, TB and Malaria<sup>41</sup> and the (United States) President's Emergency Plan for AIDS Relief (PEPFAR)<sup>42</sup> and associated increases in representative HIV surveillance and behaviour data from sentinel sites and from Demographic and Health Surveys with HIV serological surveys (DHS+) has increased both the imperative and the opportunities for testing the large-scale success of interventions. Large-scale interventions must be associated with the collection of sufficiently-detailed data to allow their evaluation using mathematical models to determine the magnitude of their impact and for its attribution to different components of the intervention. DHS+ and second-generation surveillance data<sup>43</sup> should be explored to determine whether it is possible to link behaviour change to particular interventions. The above-described methods using observational studies in conjunction with mathematical models have the advantage of exploring the actual implementation of interventions at the scale of interest, and, if performed rigorously, provide a set of tools for epidemiology and the development of health policy.

### **Contributions**

All the authors developed and contributed to the ideas within the manuscript. TBH programmed and analysed the model advised by GPG and PJW. All authors contributed to drafting the manuscript.

### **Competing Interests**

The authors declare that there are no competing interests.

### **Statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in STI and any other BMJPGJL products and sublicenses such use and exploit all subsidiary rights, as set out in our licence (<http://sti.bmjournals.com/ifora/licence.pdf>).

### **Acknowledgments**

For funding support, TBH thanks the Wellcome Trust, PJW thanks UNAIDS and GPG thanks the UK Medical Research Council. The authors thank Dr Simon Gregson for thoughtful suggestions which helped improve the manuscript.

### **Figure Legends**

#### ***Figure 1***

Modelled HIV prevalence and incidence in a generalised epidemic assuming no behaviour change (solid line) and behaviour change amounting to a 50% reduction in the risk of infection. The timing of this behaviour change occurs in year 1990, 1995 or 2000 (arrows).

#### ***Figure 2***

The epidemic in Kampala, Uganda and the effect of 'ABC' interventions. HIV epidemic model fitted (blue line 'ABC') to ANC HIV prevalence estimates (black bars with 95% confidence intervals); source - US. Census Bureau<sup>44</sup>. Also shown are epidemic projections assuming no behavioural change (black line), increases in condom use (red line 'C'), and increase in condom use and 2 year average delay in first sex (green line 'AC'), parameterised according to observed behaviour change<sup>26</sup>. The horizontal dashed line shows peak prevalence and is for ease of reading.

## References

1. Stover, J. et al. The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. *Science* **311**, 1474-6 (2006).
2. Boerma, J.T. et al. Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. *Bull World Health Organ* **84**, 145-50 (2006).
3. Salomon, J.A. et al. Integrating HIV prevention and treatment: from slogans to impact. *PLoS Med* **2**, e16 (2005).
4. Grassly, N.C., Garnett, G.P., Schwartlander, B., Gregson, S. & Anderson, R.M. The effectiveness of HIV prevention and the epidemiological context. *Bull World Health Organ* **79**, 1121-32 (2001).
5. UNAIDS. 2006 Report on the global AIDS epidemic. [http://www.unaids.org/en/HIV\\_data/2006GlobalReport/default.asp](http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp) (Geneva, 2006).
6. Stephenson, J.M. & Cowan, F.M. Evaluating interventions for HIV prevention in Africa. *Lancet* **361**, 633-4 (2003).
7. Aral, S.O. & Peterman, T.A. Do we know the effectiveness of behavioural interventions? *Lancet* **351 Suppl 3**, 33-6 (1998).
8. Crepaz, N. et al. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. *Aids* **20**, 143-57 (2006).
9. Manhart, L.E. & Holmes, K.K. Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? *J Infect Dis* **191 Suppl 1**, S7-24 (2005).
10. Kajubi, P. et al. Increasing condom use without reducing HIV risk: results of a controlled community trial in Uganda. *J Acquir Immune Defic Syndr* **40**, 77-82 (2005).
11. Avert, B. et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS Med* **2**, e298 (2005).
12. Johnson, W.D. et al. HIV intervention research for men who have sex with men: a 7-year update. *AIDS Educ Prev* **17**, 568-89 (2005).
13. Herbst, J.H. et al. A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men. *J Acquir Immune Defic Syndr* **39**, 228-41 (2005).
14. Elwy, A.R., Hart, G.J., Hawkes, S. & Petticrew, M. Effectiveness of interventions to prevent sexually transmitted infections and human immunodeficiency virus in heterosexual men: a systematic review. *Arch Intern Med* **162**, 1818-30 (2002).
15. Semaan, S. et al. A profile of U.S.-based trials of behavioral and social interventions for HIV risk reduction. *J Acquir Immune Defic Syndr* **30 Suppl 1**, S30-50 (2002).
16. Siegfried, N., Clarke, M. & Volmink, J. Randomised controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution  
10.1136/bmj.331.7519.742. *BMJ* **331**, 742- (2005).
17. Eames, K.T. & Keeling, M.J. Modeling dynamic and network heterogeneities in the spread of sexually transmitted diseases. *Proc Natl Acad Sci U S A* **99**, 13330-5 (2002).
18. Garnett, G.P. & Anderson, R.M. Sexually transmitted diseases and sexual behavior: insights from mathematical models. *J Infect Dis* **174 Suppl 2**, S150-61 (1996).
19. Ghani, A.C. & Garnett, G.P. Risks of acquiring and transmitting sexually transmitted diseases in sexual partner networks. *Sex Transm Dis* **27**, 579-87 (2000).
20. Grosskurth, H. et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. *Lancet* **346**, 530-6 (1995).
21. Wawer, M.J. et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. *Lancet* **353**, 525-35 (1999).
22. Kamali, A. et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. *Lancet* **361**, 645-52 (2003).
23. Gregson, S. & Garnett, G.P. The efficacy of viability of integrated behavioural and STD management interventions to control the spread of HIV infection: findings from in-depth studies in Manicaland, Zimbabwe. in *16th Biennial meeting of the International Society for Sexually Transmitted Diseases Research* (Amsterdam, 2005).
24. Susser, M. Some principles in study design for preventing HIV transmission: rigor or reality. *Am J Public Health* **86**, 1713-6 (1996).
25. White, R.G. et al. Can Population Differences Explain the Contrasting Results of the Mwanza, Rakai, and Masaka HIV/Sexually Transmitted Disease Intervention Trials?: A Modeling Study. *J Acquir Immune Defic Syndr* **37**, 1500-1513 (2004).
26. Asiiimwe-Okiror, G. et al. Change in sexual behaviour and decline in HIV infection among young pregnant women in urban Uganda. *Aids* **11**, 1757-63 (1997).
27. Kilian, A.H. et al. Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. *Aids* **13**, 391-8 (1999).

28. Nelson, K.E. et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. *N Engl J Med* **335**, 297-303 (1996).
29. Rojanapithayakorn, W. & Hanenberg, R. The 100% condom program in Thailand. *Aids* **10**, 1-7 (1996).
30. Gregson, S. et al. HIV decline associated with behavior change in eastern Zimbabwe. *Science* **311**, 664-6 (2006).
31. Lewis, J.J., Ronsmans, C., Ezeh, A. & Gregson, S. The population impact of HIV on fertility in sub-Saharan Africa. *Aids* **18 Suppl 2**, S35-43 (2004).
32. Garnett, G.P. & Gregson, S. Monitoring the course of the HIV-1 epidemic: the influence of patterns of fertility on HIV-1 prevalence estimates. *Mathematical Population Studies* **8**, 251-277 (2000).
33. Stoneburner, R.L. & Low-Beer, D. Population-level HIV declines and behavioral risk avoidance in Uganda. *Science* **304**, 714-8 (2004).
34. Hogle, A.J. What happened in Uganda? Declining HIV prevalence, behavior change and the national response. (U.S. Agency for International development., 2002).
35. Hallett, T.B. et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. *Sex Transm Infect* **82**, i1-8 (2006).
36. Garnett, G.P., Gregson, S. & Stanecki, K.A. Criteria for detecting and understanding changes in the risk of HIV infection at a national level in generalised epidemics. *Sex Transm Infect* **82**, i48-51 (2006).
37. Hallett, T.B. et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. *Sex Transm Infect* **82 Suppl 1**, i1-i8 (2006).
38. Mahomva, A. et al. HIV prevalence and trends from data in Zimbabwe, 1997-2004. *Sex Transm Infect* **82 Suppl 1**, i42-7 (2006).
39. UNAIDS. Evidence for HIV decline in Zimbabwe: a comprehensive review of the epidemiological data. [www.epidem.org](http://www.epidem.org) (2005).
40. Boerma, J.T. & Weir, S.S. Integrating demographic and epidemiological approaches to research on HIV/AIDS: the proximate-determinants framework. *J Infect Dis* **191 Suppl 1**, S61-7 (2005).
41. The Global Fund to Fight AIDS Tuberculosis and Malaria. The Global Fund to Fight AIDS, Tuberculosis and Malaria. (2004).
42. Office of the United States Global AIDS Coordinator. The President's Emergency Plan for AIDS Relief. U.S. Five-year global HIV/AIDS strategy. (2004).
43. World Health Organization/United Nations Joint Programme on AIDS. Second Generation Surveillance for HIV: the Next Decade. (Geneva, 2000).
44. US Census Bureau. HIV/AIDS Surveillance data base. (2004).



Figure 1





Figure 2

